In continuation of our Letter dated 1st November, 2025 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday, 8th November, 2025 at Shop No ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare's board, meeting on November 8, 2025, approved the unaudited standalone and consolidated financial results for Q2 FY26 (quarter ended September 30, 2025) and H1 FY26. On a standalone basis, Q2 revenue from operations stood at Rs. 193.53 lakhs versus Rs. 197.98 lakhs in Q2 FY25, with net profit at Rs. 31.04 lakhs (vs Rs. 56.30 lakhs YoY). H1 FY26 standalone net profit fell sharply to Rs. 64.77 lakhs from Rs. 114.67 lakhs a year earlier. Consolidated Q2 net profit came in at Rs. 33.15 lakhs with H1 FY26 consolidated profit at Rs. 54.42 lakhs versus Rs. 120.74 lakhs YoY. Statutory auditors Maheshwari & Co. issued an unmodified limited review report for both sets of results. The company operates in a single segment (Medical and Healthcare Services) and reports one subsidiary, Tej Vedaant Healthcare Private Limited.
Year-on-year profitability has weakened meaningfully — standalone H1 net profit is down roughly 44% and EPS has nearly halved, which may pressure the stock in the short term despite the quarter-over-quarter improvement on a consolidated basis. Investors should watch for commentary on revenue trajectory and cost control in upcoming quarters.